A recent FDA advisory committee decision has sparked debate about the expanding peptide market, particularly regarding their distribution through compounding pharmacies. These facilities operate under minimal regulatory oversight while managing a multi-billion dollar industry. The endorsement of broader peptide usage raises concerns about prescription patterns, safety monitoring, and the adequacy of current regulatory frameworks governing these establishments. Industry experts and health authorities debate whether existing guidelines sufficiently protect consumers in this rapidly growing sector.

Summary auto-generated by AI from the original publisher's content. Editorial standards.